Trilogy Capital Inc. Makes New $2.37 Million Investment in Intuitive Surgical, Inc. $ISRG

Key Points

• Trilogy Capital Inc. invested approximately $2.37 million in Intuitive Surgical, purchasing 4,368 shares during the 2nd quarter.
• Institutional investors now hold 83.64% of Intuitive Surgical's stock, reflecting significant confidence in the company amid varied equity research ratings.
• Intuitive Surgical reported a 21.4% increase in revenue from the previous year, with earnings per share of $2.19 surpassing analyst expectations of $1.93.

Trilogy Capital Inc. bought a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 4,368 shares of the medical equipment provider's stock, valued at approximately $2,374,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Aaron Wealth Advisors LLC grew its position in shares of Intuitive Surgical by 0.8% in the 2nd quarter. Aaron Wealth Advisors LLC now owns 2,528 shares of the medical equipment provider's stock valued at $1,374,000 after buying an additional 19 shares during the last quarter. Crown Wealth Group LLC grew its position in shares of Intuitive Surgical by 4.8% in the 1st quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock valued at $218,000 after buying an additional 20 shares during the last quarter. FSM Wealth Advisors LLC boosted its holdings in shares of Intuitive Surgical by 3.8% in the first quarter. FSM Wealth Advisors LLC now owns 546 shares of the medical equipment provider's stock valued at $270,000 after acquiring an additional 20 shares during the period. CFO4Life Group LLC boosted its holdings in shares of Intuitive Surgical by 4.8% in the first quarter. CFO4Life Group LLC now owns 436 shares of the medical equipment provider's stock valued at $216,000 after acquiring an additional 20 shares during the period. Finally, J. W. Coons Advisors LLC boosted its holdings in shares of Intuitive Surgical by 1.4% in the first quarter. J. W. Coons Advisors LLC now owns 1,497 shares of the medical equipment provider's stock valued at $741,000 after acquiring an additional 20 shares during the period. Institutional investors and hedge funds own 83.64% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ISRG shares. Wall Street Zen downgraded Intuitive Surgical from a "buy" rating to a "hold" rating in a report on Friday, September 26th. BTIG Research reissued a "buy" rating and issued a $571.00 price objective on shares of Intuitive Surgical in a report on Wednesday. Truist Financial increased their price objective on Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Wells Fargo & Company increased their price objective on Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a report on Wednesday, July 23rd. Finally, The Goldman Sachs Group decreased their price objective on Intuitive Surgical from $621.00 to $567.00 and set a "buy" rating for the company in a report on Wednesday. Fourteen investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $594.19.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $438.04 on Thursday. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00. The business has a fifty day moving average of $465.33 and a two-hundred day moving average of $500.54. The company has a market cap of $157.03 billion, a P/E ratio of 61.09, a price-to-earnings-growth ratio of 4.69 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The company had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. During the same quarter last year, the company earned $1.78 earnings per share. Intuitive Surgical's quarterly revenue was up 21.4% compared to the same quarter last year. Sell-side analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, insider Gary S. Guthart sold 29,360 shares of Intuitive Surgical stock in a transaction on Friday, August 29th. The stock was sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the completion of the transaction, the insider owned 19,827 shares of the company's stock, valued at $9,368,059.23. The trade was a 59.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Amy L. Ladd sold 335 shares of Intuitive Surgical stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $440.69, for a total value of $147,631.15. Following the transaction, the director directly owned 739 shares of the company's stock, valued at $325,669.91. This trade represents a 31.19% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,224 shares of company stock valued at $21,716,492. 0.70% of the stock is owned by company insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.